Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Pfizer’s $345M EpiPen Price-Gouge Deal Gets Initial Court Nod

July 26, 2021, 6:25 PM

The EpiPen buyers leading price-gouging litigation against two top drugmakers won preliminary approval from a federal judge in Kansas for their $345 million settlement with Pfizer Inc. affiliates that formerly manufactured the lifesaving allergy treatment sold by Mylan NV.

Judge Daniel D. Crabtree signed off tentatively on the agreement, which would resolve class action antitrust claims brought against Pfizer in the U.S. District Court for the District of Kansas on behalf of “end payers” like the insurers, pension funds, and consumers that have targeted the two drug giants.

The deal disclosed July 15 is “the result of serious, extensive ...